Expertise in
15
conditions

Dr. Cora N. Sternberg

Oncology
Weill Medical College Of Cornell
1305 York Ave, Suite 12, 
New York, NY 
Offers Telehealth
Expertise in
15
conditions
Weill Medical College Of Cornell
1305 York Ave, Suite 12, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Cora Sternberg is an Oncologist in New York, New York. Dr. Sternberg is highly rated in 15 conditions, according to our data. Her top areas of expertise are Prostate Cancer, Urothelial Cancer, Renal Cell Carcinoma (RCC), Orchiectomy, and Nephrectomy.

Her clinical research consists of co-authoring 354 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in NY
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health First
  • HMO
  • POS
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

WEILL MEDICAL COLLEGE OF CORNELL
1305 York Ave, Suite 12, New York, NY 10021

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Gemcitabine Hydrochloride, Pembrolizumab
Study Phase: Phase 2
A Single Arm, Multicenter, Phase 2 Trial to Evaluate the Efficacy of Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
A Single Arm, Multicenter, Phase 2 Trial to Evaluate the Efficacy of Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
Enrollment Status: Terminated
Publish Date: March 21, 2025
Intervention Type: Procedure, Drug
Study Drugs: Lenvatinib, Pembrolizumab
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 31, 2024
Intervention Type: Drug
Study Drug: Fuzuloparib+Abiraterone Acetate+Prednisone
Study Phase: Phase 3
A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer
A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2024
Intervention Type: Other, Radiation, Drug
Study Drugs: Abiraterone acetate, Docetaxel
Study Phase: Phase 3
Phase II Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH)
Phase II Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH)
Enrollment Status: Completed
Publish Date: October 16, 2024
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
ODM-201 Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Non-progressive Disease After Subsequent Treatment With a Taxane: A Multicenter Randomized Double-blind Placebo-controlled Phase II Trial.
ODM-201 Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Non-progressive Disease After Subsequent Treatment With a Taxane: A Multicenter Randomized Double-blind Placebo-controlled Phase II Trial.
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Other, Drug
Study Drug: ODM-201
Study Phase: Phase 2
View 5 Less Clinical Trials

352 Total Publications

Cell-free DNA whole-genomes reveal chromosomal rearrangements associated with heterogeneity and stem cell-like castration-resistant prostate cancer.
Cell-free DNA whole-genomes reveal chromosomal rearrangements associated with heterogeneity and stem cell-like castration-resistant prostate cancer.
Journal: medRxiv : the preprint server for health sciences
Published: July 09, 2025
Similar Doctors
Expertise in
25
conditions
Dr. Steven M. Horwitz
Oncology
Expertise in
25
conditions
Dr. Steven M. Horwitz
Oncology

Memorial Hematology Lymphoma Group

530 E 74th St, 
New York, NY 
 (0.3 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Steven Horwitz is an Oncologist in New York, New York. Dr. Horwitz is highly rated in 25 conditions, according to our data. His top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, and Bone Marrow Aspiration.

Expertise in
22
conditions
Dr. Andrew D. Zelenetz
Oncology
Expertise in
22
conditions
Dr. Andrew D. Zelenetz
Oncology

Memorial Hematology Lymphoma Group

530 E 74th St, 
New York, NY 
 (0.3 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Zelenetz is an Oncologist in New York, New York. Dr. Zelenetz is highly rated in 22 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma (MCL), and Diffuse Large B-Cell Lymphoma (DLBCL).

Expertise in
33
conditions
Dr. Sandra Dangelo
Oncology
Expertise in
33
conditions
Dr. Sandra Dangelo
Oncology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (0.1 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sandra Dangelo is an Oncologist in New York, New York. Dr. Dangelo is highly rated in 33 conditions, according to our data. Her top areas of expertise are Adult Soft Tissue Sarcoma, Synovial Sarcoma, Merkel Cell Carcinoma, Liposarcoma, and Liver Embolization.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sternberg's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile